Sorafenib for the treatment of unresectable hepatocellular carcinoma.

Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis. Am J Transl Res (2014) 0.98

Apoptotic and inhibitory effects on cell proliferation of hepatocellular carcinoma HepG2 cells by methanol leaf extract of Costus speciosus. Biomed Res Int (2014) 0.92

Decorin interferes with platelet-derived growth factor receptor signaling in experimental hepatocarcinogenesis. FEBS J (2013) 0.89

Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study. Exp Ther Med (2011) 0.88

Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. Cell Biochem Biophys (2012) 0.82

Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma. J Gastroenterol (2011) 0.81

HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. Oncotarget (2016) 0.81

Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med (2011) 0.79

Sorafenib combined with cryoablation to treat unresectable hepatocellular carcinoma. Chin J Cancer Res (2011) 0.78

Biological evaluation of a novel sorafenib analogue, t-CUPM. Cancer Chemother Pharmacol (2014) 0.77

Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med (2012) 0.76

Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. Oncotarget (2016) 0.76

Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma. Mol Clin Oncol (2015) 0.75

Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Management of hepatocellular carcinoma. Hepatology (2005) 27.42

Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26

Population genomics of human gene expression. Nat Genet (2007) 24.49

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07

Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med (1999) 17.03

High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 8.67

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov (2006) 6.88

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res (2006) 6.66

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol (2004) 5.12

Tumor regression by targeted gene delivery to the neovasculature. Science (2002) 4.78

Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet (2008) 4.01

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol (2006) 3.19

The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther (1999) 2.89

Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol (1999) 2.75

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst (2005) 2.73

International trends and patterns of primary liver cancer. Int J Cancer (2001) 2.50

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol (2006) 2.25

Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology (1998) 2.14

Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol (2003) 2.08

New therapies for hepatocellular carcinoma. Oncogene (2006) 2.05

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci (2007) 2.01

Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology (1998) 1.97

Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer (1988) 1.83

Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res (1999) 1.77

Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg (2004) 1.62

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol (2003) 1.55

Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun (1997) 1.53

Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res (1995) 1.51

Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology (2007) 1.39

Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol (1997) 1.36

Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol (2003) 1.36

Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene (2001) 1.29

Report of the 16th follow-up survey of primary liver cancer. Hepatol Res (2005) 1.25

Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res (2004) 1.12

Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol (2002) 1.03

A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer (2005) 0.96

Hepatitis B virus X protein stimulates the mitochondrial translocation of Raf-1 via oxidative stress. J Virol (2007) 0.94

Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors. Oncology (1992) 0.78